- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01628965
A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients
An Open-label Long-term Extension Trial From Phase II/III of SPM962 (243-07-001) in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Chubu Region, Japan
-
Hokkaido Region, Japan
-
Kanto Region, Japan
-
Kinki Region, Japan
-
Kyushu Region, Japan
-
Shikoku Region, Japan
-
Tohoku Region, Japan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject completed the preceding trial 243-07-001 (NCT00537485)
Exclusion Criteria:
- Subject discontinued from the preceding trial 243-07-001.
- Subject had a serious adverse event which association with the investigational drug was not ruled out during trial 243-07-001.
- Subject has a persistent serious adverse event at the baseline, which was observed and association with the investigational drug was ruled out during trial 243-07-001.
- Subject had persistent hallucination or delusion during trial 243-07-001.
- Subject has psychiatric conditions such as confusion, excitation, delirium, abnormal behaviour at the baseline.
- Subject has orthostatic hypotension or a systolic blood pressure (SBP) <= 100 mmHg and has a decrease of SBP from spine to standing position >= 30 mmHg at baseline.
- Subject has a history of epilepsy, convulsion etc. during trial 243-07-001.
- Subject develops serious ECG abnormality at the baseline.
- Subject has QTc-interval >= 500 msec at the baseline or subject has an increase of QTc-interval >= 60 msec from the baseline in the trial 243-07-001 and has a QTc-interval > 470 msec in female or > 450 msec in male at the baseline.
- Subject has a serum potassium level < 3.5 mEq/L at the end of the taper period in trial 243-07-001.
- Subject has a total bilirubin >= 3.0 mg/dL or AST(GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or >= 100 IU/L) at the end of the period in trial 243-07-001.
- Subject has BUN >= 30 mg/dL or serum creatinine >= 2.0 mg/dl at the end of the taper period in trial 243-07-001.
- Subject who plans pregnancy during the trial.
- Subject has dementia.
- Subject is unable to give consent.
- Subject is judged to be inappropriate for this trial by the investigator for the reasons other than above.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SPM 962
SPM 962 transdermal patch
|
SPM 962 transdermal patch once a daily up to 36.0 mg/day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters
Time Frame: Up to 55 weeks after dosing
|
Incidence and severity of adverse events, vital signs, and laboratory parameters up to 54 weeks after dosing. *decrease in difference between supine and standing systolic blood pressure |
Up to 55 weeks after dosing
|
Skin Irritation Score of the Application Site
Time Frame: Up to 55 weeks after dosing
|
Skin irritation score of the application site were evaluated according to the criteria below. The worst score throughout the treatment period was used in the analysis. -: no reaction, ±: mild erythema, +: erythema, ++: erythema and Oedema, +++: erythema and oedema and rash papular, or serous papule, or vesicles, ++++: bullosum |
Up to 55 weeks after dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total of Unified Parkinson's Disease Rating Scale (UPDRS) Part 2 Sum Score and Part 3 Sum Score
Time Frame: Baseline, Up to 54 weeks after dosing
|
Mean change (LOCF) from baseline in Total of UPDRS Part 2 sum score and Part 3 sum up to 54 weeks after dosingUPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment.
The UPDRS consists of the following four sub-scales.
Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications.
Part 2 assesses 13 items and Part 3 assesses 14 items.
Each item is scored from 0 (normal) to 4 (severe).
The sum score serves as the sub-scale score.
A higher score indicates a greater severity of symptoms.
Thus a decrease in the scores means improvement.
|
Baseline, Up to 54 weeks after dosing
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Dopamine Agonists
- Dopamine Agents
- Rotigotine
Other Study ID Numbers
- 243-07-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
BlueRock TherapeuticsMemorial Sloan Kettering Cancer CenterActive, not recruitingAdvanced Parkinson's DiseaseUnited States, Canada
Clinical Trials on SPM 962
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs SyndromeJapan
-
UCB PharmaCompletedParkinson Disease, IdiopathicGermany
-
Otsuka Pharmaceutical Co., Ltd.CompletedParkinson's DiseaseJapan
-
Otsuka Pharmaceutical Co., Ltd.CompletedEarly Parkinson's DiseaseJapan
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs SyndromeJapan
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs Syndrome
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Pharmaceutical Co., Ltd.CompletedParkinson's DiseaseJapan